Nicox 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Gavin Spencer

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

CEO

Gavin Spencer (54 yo)

less than a year

테뉴어

Dr. Gavin M. Spencer is Director at Nicox S.A. since 2024 and serves as its Chief Executive Officer since February 28, 2024 and served as its Executive Vice-President and Chief Business Officer and served...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gavin Spencer	CEO & Director	less than a year	데이터 없음	데이터 없음
Sandrine Gestin	Vice President of Finance	no data	데이터 없음	데이터 없음
Doug Hubatsch	Executive VP & Chief Scientific Officer	2.8yrs	데이터 없음	데이터 없음
Ramesh Krishnamoorthy	Senior Director and Head of Late Stage CMC & Quality Control	5.1yrs	데이터 없음	데이터 없음
Jose Boyer	Consultant	3.8yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: 0RCQ 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gavin Spencer	CEO & Director	less than a year	데이터 없음	데이터 없음
Maurizio PetitBon	Observer	less than a year	데이터 없음	데이터 없음
Marc Le Bozec	Independent Director	less than a year	데이터 없음	데이터 없음
Robert Fechtner	Chairman of Glaucoma Clinical Advisory Board	5.8yrs	데이터 없음	데이터 없음
Robert Weinreb	Member of Glaucoma Clinical Advisory Board	3.3yrs	데이터 없음	데이터 없음
Damian Marron	Independent Chair	less than a year	데이터 없음	데이터 없음
Christine Placet	Director	less than a year	데이터 없음	데이터 없음
Donald Budenz	Member of Glaucoma Clinical Advisory Board	5.8yrs	데이터 없음	데이터 없음
Steven Mansberger	Member of Glaucoma Clinical Advisory Board	5.8yrs	데이터 없음	데이터 없음
Thomas Walters	Member of Glaucoma Clinical Advisory Board	5.8yrs	데이터 없음	데이터 없음
Sanjay Asrani	Member of Glaucoma Clinical Advisory Board	3.3yrs	데이터 없음	데이터 없음
Sonia Benhamida	Observer	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: 0RCQ 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Nicox 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Nicox S.A. Announces Board Changes

Nicox S.A., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

Nicox S.A., Annual General Meeting, Feb 28, 2023

Nicox S.A., Annual General Meeting, Feb 14, 2023

Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Recent updates

New major risk - Financial data availability

Nicox SA Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470

No longer forecast to breakeven

Nicox S.A. Announces Board Changes

New minor risk - Shareholder dilution

Nicox S.A., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

New minor risk - Financial data availability

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Full year 2022 earnings released

Nicox S.A., Annual General Meeting, Feb 28, 2023

Nicox S.A., Annual General Meeting, Feb 14, 2023

Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma

Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial

First half 2022 earnings released: EPS: €0 (vs €0.32 loss in 1H 2021)

Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Nicox S.A., Annual General Meeting, Jun 28, 2022

Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Nicox S.A. Announces Executive Changes

Nicox S.A., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: €1.17 loss per share (vs €0.54 loss in FY 2020)

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Formulation Patent for NCX 470

Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical Trial Suggesting That Once-Daily Dosed NCX 4251

Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induced by Endothelin-1

First half 2021 earnings released

Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial

High number of new and inexperienced directors

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial

Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 470

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the World Glaucoma E-Congress 2021

Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Nicox S.A., Annual General Meeting, Apr 14, 2021

Full year 2020 earnings released

Nicox S.A. to Report Fiscal Year 2020 Results on Mar 01, 2021

Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds

Nicox S.A. Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Nicox S.A. has completed a Follow-on Equity Offering in the amount of €15.000651 million.

Nicox SA Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Nicox SA Nicox Announces Senior Management Change

Nicox S.A. to Report First Half, 2020 Results on Sep 10, 2020

GHO Capital Fund I LP managed by GHO Capital Partners LLP entered into an agreement to acquire remaining unknown minority stake in VISUfarma B.V from Nicox S.A. (ENXTPA:COX) for €5 million

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령